AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12108078 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose containing formula (Bebilon Neonatal - BN group)
Number of subjects: 80
Study 12108078 — intervention group
Group type: COMPARATOR
Intervention: Lactose free formula (Pregestimil - PG group)
Number of subjects: 80
Study 9337185 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1829
Study 9337185 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1829
Study 9337185 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endpoint (cardiac death or MI)
Number of subjects: 1829
Study 9337185 — intervention group
Group type: EXPERIMENTAL
Intervention: MI after CABG
Number of subjects: 1829
Study 9337185 — intervention group
Group type: EXPERIMENTAL
Intervention: MI after PTCA
Number of subjects: 1829
Study 9337185 — intervention group
Group type: EXPERIMENTAL
Intervention: MI
Number of subjects: 1829
Study 8461240 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release ibuprofen (once-daily dosing)
Number of subjects: 578
Study 8461240 — intervention group
Group type: COMPARATOR
Intervention: Conventional-release ibuprofen (400 mg four times daily)
Number of subjects: 578
Study 2879733 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 12
Study 2879733 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 20 mg
Number of subjects: 12
Study 2879733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28335697 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored cognitive-behavioral therapy program
Number of subjects: 0
Study 28335697 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25673525 — intervention group
Group type: EXPERIMENTAL
Intervention: Family partnership intervention
Number of subjects: 117
Study 25673525 — intervention group
Group type: COMPARATOR
Intervention: Patient-family education
Number of subjects: 117
Study 25673525 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 117
Study 25332473 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein intake (30%E) with low saturated fat (7%E)
Number of subjects: 158
Study 25332473 — intervention group
Group type: COMPARATOR
Intervention: Moderate protein intake (20%E) with low saturated fat (7%E)
Number of subjects: 158
Study 25332473 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein intake (30%E) with high saturated fat (15%E)
Number of subjects: 158
Study 25332473 — intervention group
Group type: COMPARATOR
Intervention: Moderate protein intake (20%E) with high saturated fat (15%E)
Number of subjects: 158
Study 22962239 — intervention group
Group type: COMPARATOR
Intervention: Deworming tablet (400 mg albendazole) once in six months
Number of subjects: 0
Study 22962239 — intervention group
Group type: EXPERIMENTAL
Intervention: Deworming tablet (400 mg albendazole) plus weekly Iron-Folic acid (60 mg elemental iron and 0.5 mg folic acid)
Number of subjects: 0
Study 20456032 — intervention group
Group type: EXPERIMENTAL
Intervention: Opaque layer firing temperature at 950 degrees C (Gr2)
Number of subjects: 60
Study 20456032 — intervention group
Group type: EXPERIMENTAL
Intervention: Opaque layer firing temperature at 1000 degrees C (Gr3)
Number of subjects: 60
Study 20456032 — intervention group
Group type: COMPARATOR
Intervention: Opaque layer firing temperature at 900 degrees C (Gr1, control)
Number of subjects: 60
Study 20456032 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical and thermal cycling
Number of subjects: 60
Study 19093922 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support system in intervention units
Number of subjects: 1118
Study 19093922 — intervention group
Group type: COMPARATOR
Intervention: No clinical decision support system in control units
Number of subjects: 1118
Study 15795344 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and motivational intervention including an ACP workbook, motivational counseling by social workers, and cues to providers to discuss ACP.
Number of subjects: 248
Study 15795344 — intervention group
Group type: COMPARATOR
Intervention: Control group received an advance directive booklet.
Number of subjects: 248
Study 12487504 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 44
Study 12487504 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study 10327093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy
Number of subjects: 0
Study 10327093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8959787 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day course of antithymocyte globulin (ATG)
Number of subjects: 30
Study 8959787 — intervention group
Group type: COMPARATOR
Intervention: 10-day course of antithymocyte globulin (ATG)
Number of subjects: 30
Study 1812477 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline retard preparation administered once daily in addition to baseline medication
Number of subjects: 26
Study 1812477 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline intake at 10 p.m.
Number of subjects: 26
Study 1812477 — intervention group
Group type: COMPARATOR
Intervention: Theophylline intake at 6 p.m. and 8 p.m.
Number of subjects: 26
Study 6440704 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 59
Study 6440704 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital
Number of subjects: 59
Study 30417636 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ HDM SLIT-tablet (ACARIZAX®) as add-on to pharmacotherapy
Number of subjects: 0
Study 30417636 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 0
Study 29324244 — intervention group
Group type: COMPARATOR
Intervention: Advantaged social status
Number of subjects: 103
Study 29324244 — intervention group
Group type: EXPERIMENTAL
Intervention: Disadvantaged social status
Number of subjects: 103
Study 27339453 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (500 mg capsules, twice daily for 4 weeks)
Number of subjects: 100
Study 27339453 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg neutral microcellulose capsules, twice daily for 4 weeks)
Number of subjects: 100
Study 25216506 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention leading to normal glucose tolerance at 6 months (NGT-6 m)
Number of subjects: 0
Study 25216506 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention leading to normal glucose tolerance at 24 months (NGT-24 m)
Number of subjects: 0
Study 25216506 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 0
Study 25216506 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion to T2DM
Number of subjects: 0
Study 23066166 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined B-vitamin treatment (folic acid 2.5mg, vitamin B(6) 50mg, vitamin B(12) 1mg)
Number of subjects: 5442
Study 23066166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5442
Study 23066166 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined B-vitamin treatment
Number of subjects: 5442
Study 20976051 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 780
Study 20976051 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine + Sulfadoxine-Pyrimethamine (AQ+SP)
Number of subjects: 780
Study 20976051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-Pyrimethamine (SP)
Number of subjects: 780
Study 20976051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 780
Study 17610459 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation plus guided imagery
Number of subjects: 20
Study 17610459 — intervention group
Group type: COMPARATOR
Intervention: Meditation
Number of subjects: 20
Study 17610459 — intervention group
Group type: COMPARATOR
Intervention: Tai chi
Number of subjects: 20
Study 17610459 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 20
Study 17610459 — intervention group
Group type: COMPARATOR
Intervention: Yoga
Number of subjects: 20
Study 17610459 — intervention group
Group type: COMPARATOR
Intervention: Hypnosis
Number of subjects: 20
Study 17610459 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation
Number of subjects: 20
Study 16276166 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone (50-mg bolus followed by a continuous infusion of 0.18 mg/kg body weight/hr, reduced to 0.06 mg/kg/hr after shock reversal)
Number of subjects: 41
Study 16276166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 16276166 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone
Number of subjects: 41
Study 11924224 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing sugar-free gum (sorbitol-sweetened), 1 stick for 15-20 minutes after meals, three times daily
Number of subjects: 547
Study 11924224 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chewing gum)
Number of subjects: 547
Study 9701189 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato-based juice supplemented with vitamin C (600 mg), vitamin E (400 IU), and beta-carotene (30 mg)
Number of subjects: 0
Study 9701189 — intervention group
Group type: COMPARATOR
Intervention: Placebo juice
Number of subjects: 0
Study 7648372 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (delivered via Turbuhaler)
Number of subjects: 16
Study 7648372 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (delivered via Rotahaler)
Number of subjects: 16
Study 2528221 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 1% cream applied twice daily
Number of subjects: 97
Study 2528221 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 97
Study 1182676 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate therapy
Number of subjects: 195
Study 1182676 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate in combination with other drugs
Number of subjects: 195
Study 31003139 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol suppression (metyrapone)
Number of subjects: 40
Study 31003139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28815547 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable single‐incision mini‐sling (SIMS) (Ajust®; n = 155)
Number of subjects: 305
Study 28815547 — intervention group
Group type: COMPARATOR
Intervention: Standard mid‐urethral slings (SMUS) (TVT, TVT‐O or TOT; n = 150)
Number of subjects: 305
Study 28815547 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable single‐incision mini‐sling (SIMS) (Ajust®)
Number of subjects: 305
Study 28815547 — intervention group
Group type: COMPARATOR
Intervention: Standard mid‐urethral slings (SMUS)
Number of subjects: 305
Study 26119672 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with negative emmprin expression
Number of subjects: 250
Study 26119672 — intervention group
Group type: COMPARATOR
Intervention: Cystectomy only cohort with emmprin expression
Number of subjects: 250
Study 23131078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 188
Study 23131078 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic therapy
Number of subjects: 188
Study 19409544 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturing embryos at low oxygen (5% O2, 89% N2)
Number of subjects: 647
Study 19409544 — intervention group
Group type: COMPARATOR
Intervention: Culturing embryos in air (5% O2)
Number of subjects: 647
Study 18763475 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally specific dance
Number of subjects: 126
Study 18763475 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 126
Study 15644672 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Enteral Nutrition (EN)
Number of subjects: 30
Study 15644672 — intervention group
Group type: COMPARATOR
Intervention: Early Parenteral Nutrition (PN)
Number of subjects: 30
Study 11911721 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity exercise (LEX, n = 24)
Number of subjects: 62
Study 11911721 — intervention group
Group type: COMPARATOR
Intervention: High-intensity exercise (HEX, n = 22)
Number of subjects: 62
Study 11911721 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 16)
Number of subjects: 62
Study 10622346 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (1.5 microg/kg, IM, at 23.00 h)
Number of subjects: 95
Study 10622346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 10622346 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 95
Study 8748367 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. nutrition plus triple therapy (heparin, hydrocortisone, glyceryl trinitrate patch)
Number of subjects: 46
Study 8748367 — intervention group
Group type: COMPARATOR
Intervention: standard i.v. nutrition (control group)
Number of subjects: 46
Study 2117424 — intervention group
Group type: EXPERIMENTAL
Intervention: Vamin 9 glucose
Number of subjects: 68
Study 2117424 — intervention group
Group type: EXPERIMENTAL
Intervention: MB233G
Number of subjects: 68
Study 6795122 — intervention group
Group type: EXPERIMENTAL
Intervention: O-acetyl-negative polysaccharide vaccine
Number of subjects: 0
Study 6795122 — intervention group
Group type: COMPARATOR
Intervention: O-acetyl-positive polysaccharide vaccine
Number of subjects: 0
Study 6795122 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 0
Study 29890569 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 50 mg daily plus placebo
Number of subjects: 138
Study 29890569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg daily plus synbiotic
Number of subjects: 138
Study 26303349 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 510
Study 26303349 — intervention group
Group type: COMPARATOR
Intervention: Sedentary time (SED)
Number of subjects: 510
Study 25023805 — intervention group
Group type: EXPERIMENTAL
Intervention: MFG and BA (combined)
Number of subjects: 448
Study 25023805 — intervention group
Group type: COMPARATOR
Intervention: Control (no MFG or BA)
Number of subjects: 448
Study 22682022 — intervention group
Group type: EXPERIMENTAL
Intervention: More Intensive (MI) regimen of tofacitinib
Number of subjects: 331
Study 22682022 — intervention group
Group type: EXPERIMENTAL
Intervention: Less Intensive (LI) regimen of tofacitinib
Number of subjects: 331
Study 22682022 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 331
Study 20860917 — intervention group
Group type: EXPERIMENTAL
Intervention: Montek®
Number of subjects: 24
Study 20860917 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomont®
Number of subjects: 24
Study 20860917 — intervention group
Group type: COMPARATOR
Intervention: Singulair®
Number of subjects: 24
Study 19072676 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT skills utilization
Number of subjects: 27
Study 15894592 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein‐energy supplementation (Atole)
Number of subjects: 450
Study 15894592 — intervention group
Group type: COMPARATOR
Intervention: Low energy/no protein supplementation (Fresco)
Number of subjects: 450
Study 15894592 — intervention group
Group type: EXPERIMENTAL
Intervention: Atole group
Number of subjects: 450
Study 12567341 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene block
Number of subjects: 18
Study 12567341 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular block
Number of subjects: 18
Study 12567341 — intervention group
Group type: COMPARATOR
Intervention: Infraclavicular block
Number of subjects: 18
Study 10575074 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait with shoes
Number of subjects: 0
Study 10575074 — intervention group
Group type: COMPARATOR
Intervention: Gait without shoes
Number of subjects: 0
Study 8757085 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified propolis
Number of subjects: 190
Study 8757085 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis saturated with anti-inflammatory trace metal elements
Number of subjects: 190
Study 8757085 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis saturated with trace metal elements
Number of subjects: 190
Study 8757085 — intervention group
Group type: EXPERIMENTAL
Intervention: Poplar bud ointment saturated with trace metal elements
Number of subjects: 190
Study 8757085 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 190
Study 1722835 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologically active helevin-based compositions (BAC)
Number of subjects: 28
Study 1722835 — intervention group
Group type: COMPARATOR
Intervention: Ointments with antibiotics and antiseptics on a fat base (Control)
Number of subjects: 28
Study 6749828 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxapine
Number of subjects: 80
Study 6749828 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 80
Study 30633202 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET) plus montelukast
Number of subjects: 72
Study 30633202 — intervention group
Group type: COMPARATOR
Intervention: Montelukast alone
Number of subjects: 72
Study 28609542 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use, laser-cut, slow-flow nipples
Number of subjects: 13
Study 28609542 — intervention group
Group type: COMPARATOR
Intervention: Standard-flow nipples
Number of subjects: 13
Study 26559412 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) in aMCI group (MD group)
Number of subjects: 200
Study 26559412 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) in control group (CD group)
Number of subjects: 200
Study 26559412 — intervention group
Group type: COMPARATOR
Intervention: Normal saline in aMCI group (MN group)
Number of subjects: 200
Study 26559412 — intervention group
Group type: COMPARATOR
Intervention: Normal saline in control group (CN group)
Number of subjects: 200
Study 25119602 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic atrophic gastritis cases
Number of subjects: 301
Study 25119602 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic superficial gastritis cases
Number of subjects: 301
Study 25119602 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 301
Study 25119602 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of gastritis cases vs healthy controls
Number of subjects: 301
Study 23084481 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation (60 Gy of conventional irradiation to the surgical bed for 6 weeks)
Number of subjects: 1005
Study 23084481 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see policy
Number of subjects: 1005
Study 23084481 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation
Number of subjects: 1005
Study 18554182 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 90-min bout of strenuous isokinetic resistance exercise (3 sets x 10 repetitions, 12 exercises at 80% of maximum peak torque production, 2-min rest between exercises)
Number of subjects: 8
Study 18554182 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 90-min bout of strenuous isokinetic resistance exercise
Number of subjects: 8
Study 17157339 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-steroid profile measured by tandem mass spectrometry during high dose cortrosyn stimulation test
Number of subjects: 0
Study 17157339 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-steroid profile
Number of subjects: 0
Study 17157339 — intervention group
Group type: EXPERIMENTAL
Intervention: Single aldosterone value
Number of subjects: 0
Study 17157339 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-deoxycortisol, dehydroepiandrosterone, and two-steroid profile
Number of subjects: 0
Study 17157339 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulated levels of aldosterone, 11-deoxycortisol, dehydroepiandrosterone, and two- or three-steroid profile
Number of subjects: 0
Study 17157339 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid profile measuring cortisol, aldosterone, 11-deoxycortisol, and dehydroepiandrosterone
Number of subjects: 0
Study 15750416 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose inductive chemotherapy, surgery, and then radiotherapy
Number of subjects: 60
Study 15750416 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery and radiotherapy only)
Number of subjects: 60
Study 15750416 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant cytostatic treatment with adequate tissue regression
Number of subjects: 60
Study 15750416 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in expressions of laminin and syndecan-1 in response to cytostatic treatment
Number of subjects: 60
Study 11772810 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg
Number of subjects: 90
Study 11772810 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 3 microg/kg
Number of subjects: 90
Study 11772810 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 90
Study 10617008 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative administration of 3000 IU of antithrombin III (AT III) concentrates plus heparin (Group A)
Number of subjects: 22
Study 10617008 — intervention group
Group type: COMPARATOR
Intervention: Heparin only (Group B)
Number of subjects: 22
Study 7671358 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/d)
Number of subjects: 447
Study 7671358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447
Study 2303172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 2303172 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 176
Study 6250928 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid Gaviscon
Number of subjects: 44
Study 6250928 — intervention group
Group type: COMPARATOR
Intervention: Antacid gel (magnesium and aluminium hydroxide)
Number of subjects: 44
Study 30985210 — intervention group
Group type: EXPERIMENTAL
Intervention: ScvO2 < 70%
Number of subjects: 1741
Study 30985210 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate levels
Number of subjects: 1741
Study 30985210 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 1741